-
1.发明申请Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses 有权凝血蛋白，凝血 - 抗凝蛋白复合物，其衍生物及其用途公开(公告)号：US20070025979A1
公开(公告)日：2007-02-01
申请号：US11451959
申请日：2006-06-13
申请人： Edward Pryzdial
发明人： Edward Pryzdial
CPC分类号： A61K31/727 , A61K38/166 , A61K38/4846 , A61K38/49 , A61K38/58 , A61K45/06 , C12Q1/37 , G01N33/6893 , G01N33/86 , G01N2333/96463 , G01N2800/224 , A61K2300/00
摘要： The present invention relates to the use of coagulation proteins and complexes thereof with anticoagulation proteins for the lysis of blood clots or other applications affected by accelerated plasmin production. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein, with or without being in complex with a serpin, comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.
摘要翻译： 本发明涉及凝血蛋白及其与抗凝蛋白的复合物在凝血酶或其它受加速纤溶酶生成影响的应用中的应用。 更具体地，本发明提供了一种通过施用包含碱性C末端氨基酸的丝氨酸蛋白酶引起的至少一种凝血蛋白加速血块溶解的方法，其中所述凝血蛋白 可以是因子X或因子V的衍生物或其组合。 还提供了用于治疗和预防血凝块的药物组合物，其中，本发明的方法和产品有利地加速凝块溶解，同时潜在地最小化与其它凝块溶解剂一起观察到的不良副作用，例如出血。 本发明还提供了一种用于检测受试者中的纤维蛋白溶解电位的方法。
-
公开(公告)号：US20060057591A1
公开(公告)日：2006-03-16
申请号：US10940642
申请日：2004-09-15
申请人： Edward Pryzdial , Melanie Derry
发明人： Edward Pryzdial , Melanie Derry
CPC分类号： C07K16/18
摘要： There is provided a method for preventing or treating viral infections using members of the annexin proteins family. In particular annexins 1 and 5 as well as inhibitors of heterotetrameric annexin 2, such as antibodies, significantly reduce the production of virus progeny.
摘要翻译： 提供了使用膜联蛋白家族成员预防或治疗病毒感染的方法。 特别是膜联蛋白1和5以及异源四聚体膜联蛋白2（例如抗体）的抑制剂显着降低病毒后代的产生。
-
公开(公告)号：US20060275277A1
公开(公告)日：2006-12-07
申请号：US10551565
申请日：2004-04-02
申请人： Edward Pryzdial
发明人： Edward Pryzdial
IPC分类号： A61K38/54 , C12Q1/37 , A61K31/727
CPC分类号： G01N33/86 , A61K31/727 , A61K38/4846 , A61K38/49 , A61K38/58 , A61K45/06 , C12Q1/37 , G01N33/6893 , G01N2333/96463 , G01N2800/224 , A61K2300/00
摘要： The present invention relates to the use of coagulation proteins for the lysis of blood clots. More specifically, the present invention provides a method for accelerating the dissolution of a blood clot through the administration of at least one coagulation protein comprising a basic C-terminal amino acid, wherein the coagulation protein may be a derivative of Factor X or Factor V or a combination thereof. Pharmaceutical compositions for the treatment and prophylaxis of blood clots are also provided, wherein, the methods and products of the present invention advantageously accelerate clot dissolution while potentially minimizing the adverse side-effects, such as hemorrhaging, seen with other clot dissolving agents. The present invention also provides a method for detecting a fibrinolytic potential in a subject.
摘要翻译： 本发明涉及凝血蛋白用于血栓溶解的用途。 更具体地，本发明提供了一种通过施用包含碱性C末端氨基酸的至少一种凝血蛋白来加速血块溶解的方法，其中凝血蛋白可以是因子X或因子Ⅴ的衍生物或 其组合。 还提供了用于治疗和预防血凝块的药物组合物，其中，本发明的方法和产品有利地加速凝块溶解，同时潜在地最小化其他凝块溶解剂所见的不良副作用，例如出血。 本发明还提供了一种用于检测受试者中的纤维蛋白溶解电位的方法。
-
公开(公告)号：US20060241039A1
公开(公告)日：2006-10-26
申请号：US11337979
申请日：2006-01-23
申请人： Edward Pryzdial , Abed Zeibdawi , Jean Grundy
发明人： Edward Pryzdial , Abed Zeibdawi , Jean Grundy
摘要： There is provided FV derivatives that reduce blood clotting activity, by reducing thrombin generation, when compared to wild-type FV. In particular, the FV of the present invention comprises single-point and multi-point mutations, encompassed by aspartic acid 79 to glutamic acid 119. The derivatives can be used to treat patient with conditions necessitating reduced clotting activity.
摘要翻译： 与野生型FV相比，提供FV衍生物，通过降低凝血酶产生，降低血液凝固活性。 特别地，本发明的FV包括天冬氨酸79至谷氨酸119所包含的单点和多点突变。该衍生物可用于治疗需要降低凝血活性的病人。
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
